ZOLPIDEM TARTRATE
Total Payments
$122,694
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $122,694 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $122,694 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An open label, single dose, randomized, 2-way crossover study1 test formulation and 1 reference drug, 3.5 mg sublingual to evaluate BE under fasted condition in healthy volunteers. | Par Pharmaceutical, Inc. | $122,694 | 0 |
Top Doctors Receiving Payments for ZOLPIDEM TARTRATE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Secaucus, NJ | $122,694 | 1 |
Ad
Manufacturing Companies
- Par Pharmaceutical, Inc. $122,694
Product Information
- Type Drug
- Total Payments $122,694
- Total Doctors 0
- Transactions 1
About ZOLPIDEM TARTRATE
ZOLPIDEM TARTRATE is a drug associated with $122,694 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Par Pharmaceutical, Inc..
Payment data is available from 2017 to 2017. In 2017, $122,694 was paid across 1 transactions to 0 doctors.
The most common payment nature for ZOLPIDEM TARTRATE is "Unspecified" ($122,694, 100.0% of total).
ZOLPIDEM TARTRATE is associated with 1 research study, including "An open label, single dose, randomized, 2-way crossover study1 test formulation and 1 reference drug, 3.5 mg sublingual to evaluate BE under fasted condition in healthy volunteers." ($122,694).